Trials / Completed
CompletedNCT02201420
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Navidea Biopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tc 99m tilmanocept |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-03-01
- Completion
- 2015-10-01
- First posted
- 2014-07-28
- Last updated
- 2016-09-27
- Results posted
- 2016-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02201420. Inclusion in this directory is not an endorsement.